Embla and Covidien have entered into a definitive agreement under which Embla will acquire Covidien’s Sleep Diagnostic business.
This includes the sleep diagnostic products sold under the Sandman brand name. Financial terms of the transaction were not disclosed. Completion of the sale is subject to customary closing conditions.
The combined entity will form the world’s largest company to focus entirely on sleep diagnostics, with close to 1,700 customers in North America and about 2,500 worldwide. Embla markets sleep diagnostic products, along with support and service.
Both Sandman and Embla have leading brand names in North America, where it’s estimated that more than 40 million people suffer from some form of sleep disorder.
It’s estimated that close to 70 percent of patients who have suffered a stroke and 60 percent of congestive heart failure patients also suffer from sleep disordered breathing.
“You can’t open a newspaper or magazine today without seeing something about sleep. We know it impacts every aspect of our lives and this acquisition puts us at the forefront of the industry,” said David Baker, president and CEO of Embla Systems.
Embla’s main offices are located in Colorado, and the company has a research and development and technical support presence at the company’s Ottawa, Canada office. The Covidien Sandman Sleep Diagnostic business is also headquartered in Ottawa, Canada.
About Embla Systems
Embla is the leader in the global sleep diagnostic market, creating medical solutions for sleep professionals and delivering value through innovative products and service excellence. The privately held company manufactures, distributes and services its products in over 65 countries, and has 120 employees worldwide.
__________
You must log in to post a comment.